The gastrointestinal parasitism in non-human primates represents a complex and dynamic facet of wildlife health with far‐reaching implications for conservation and public health. Researchers have ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, presented ...

(RTTNews) - iBio, Inc. (IBIO) Monday reported encouraging data from a non-GLP non-human primate (NHP) pharmacokinetics study of the company's lead drug candidate IBIO-600 for the treatment of obesity.

SUZHOU, China, SAN FRANCISCO and BOSTON, March 24, 2026 /PRNewswire/ -- HKeyBio, a global leading CRO specializing in ...

Researchers say the sperm whale birth is among the first pieces of evidence of a non-primate animal participating in a cooperative birth ...

New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of efficacy on fat reduction and body composition Mouse study shows IBIO-610 ...

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo ...

During the height of the pandemic, Jennifer Kwon, PhD, became one of the first scientists hired by a new company focused on epigenome editing—Tune Therapeutics. She joined the company almost ...

The US Food and Drug Administration (FDA) has debuted a framework that is designed to help companies move away from the use of non-human primate preclinical toxicology testing. Image credit: ...